The identification of these different Sox2 target genes and Sox2 binding partners have the potential to highlight novel and clinically targetable pathways to prevent and/or treat castration-resistant prostate tumor formation and metastatic growth. This evidence concerns the gene SOX2 and prostate neoplasm.